Trader Biodesix, Inc. - BDSX CFD
Ajouter aux favoris- Résumé
- Données historiques
- Événements
- Compte de résultat
- Bilan
- Flux de trésorerie
- Capital
Conditions de trading
| Écart | 0.0562 | ||||||||
|
Frais de position longue en overnight
Long position overnight fee
Aller vers la plateforme | -0.030779% | ||||||||
|
Frais de position courte en overnight
Short position overnight fee
Aller vers la plateforme | -0.013666% | ||||||||
| Durée des frais en overnight | 22:00 (UTC) | ||||||||
| Quantité minimale négociée | 1 | ||||||||
| Devise | USD | ||||||||
| Marge | 20% | ||||||||
| Bourse | United States of America | ||||||||
| Commission sur la négociation | 0% |
*Information provided by Capital.com
Chiffres clés
| Fermeture précédente* | 1.9069 |
| Ouvert* | 1.9269 |
| Variation sur 1 an* | -44.63% |
| Fourchette du jour* | 1.837 - 1.9569 |
| Fourchette sur 52 semaines | 0.96-3.87 |
| Volume moyen (10 jours) | 141.66K |
| Volume moyen (3 mois) | 4.10M |
| Capitalisation boursière | 138.35M |
| Ratio C/B | -100.00K |
| Actions en circulation | 71.69M |
| Revenu | 35.83M |
| EPS | -1.73 |
| Dividende (rendement en %) | N/A |
| Bêta | -100.00K |
| Prochaine date de publication des résultats | Mar 13, 2023 |
Toutes les données sont fournies par Refinitiv, à l'exception des données marquées d'un astérisque, qui sont des *données fournies par Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Clôture | Change | Change (%) | Ouverture | High | Low |
|---|---|---|---|---|---|---|
| Feb 8, 2023 | 1.9169 | -0.0299 | -1.54% | 1.9468 | 1.9569 | 1.8370 |
| Feb 7, 2023 | 1.9069 | -0.0300 | -1.55% | 1.9369 | 1.9968 | 1.8370 |
| Feb 6, 2023 | 1.9768 | 0.0499 | 2.59% | 1.9269 | 2.0168 | 1.9269 |
| Feb 3, 2023 | 1.9169 | -0.1498 | -7.25% | 2.0667 | 2.1067 | 1.7871 |
| Feb 2, 2023 | 2.1466 | -0.2296 | -9.66% | 2.3762 | 2.4262 | 2.1266 |
| Feb 1, 2023 | 2.3263 | -0.1099 | -4.51% | 2.4362 | 2.4362 | 2.2663 |
| Jan 31, 2023 | 2.3862 | -0.0399 | -1.64% | 2.4261 | 2.5061 | 2.3262 |
| Jan 30, 2023 | 2.3862 | -0.0299 | -1.24% | 2.4161 | 2.4561 | 2.2663 |
| Jan 27, 2023 | 2.4661 | 0.1598 | 6.93% | 2.3063 | 2.4961 | 2.2963 |
| Jan 26, 2023 | 2.3163 | -0.0200 | -0.86% | 2.3363 | 2.4961 | 2.2763 |
| Jan 25, 2023 | 2.3563 | -0.0399 | -1.67% | 2.3962 | 2.4561 | 2.2663 |
| Jan 24, 2023 | 2.3463 | 0.0200 | 0.86% | 2.3263 | 2.3962 | 2.3063 |
| Jan 23, 2023 | 2.3263 | 0.0100 | 0.43% | 2.3163 | 2.3962 | 2.2264 |
| Jan 20, 2023 | 2.3862 | 0.1498 | 6.70% | 2.2364 | 2.3862 | 2.1965 |
| Jan 19, 2023 | 2.2165 | -0.0199 | -0.89% | 2.2364 | 2.2365 | 2.1765 |
| Jan 18, 2023 | 2.2464 | -0.1697 | -7.02% | 2.4161 | 2.4162 | 2.1665 |
| Jan 17, 2023 | 2.3862 | -0.0799 | -3.24% | 2.4661 | 2.4861 | 2.3462 |
| Jan 13, 2023 | 2.4761 | 0.1498 | 6.44% | 2.3263 | 2.4861 | 2.2464 |
| Jan 12, 2023 | 2.4661 | 0.0599 | 2.49% | 2.4062 | 2.4661 | 2.3262 |
| Jan 11, 2023 | 2.3862 | -0.0100 | -0.42% | 2.3962 | 2.4561 | 2.2464 |
Biodesix, Inc. Events
| Time (UTC) | Country | Event |
|---|---|---|
| No events scheduled | ||
- Annuel
- Trimestriel
| 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|
| Revenu total | 20.432 | 24.552 | 45.557 | 54.506 |
| Revenu | 20.432 | 24.552 | 45.557 | 54.506 |
| Coût des recettes, total | 4.406 | 6.074 | 21.998 | 30.518 |
| Résultat brut | 16.026 | 18.478 | 23.559 | 23.988 |
| Total des frais d'exploitation | 44.095 | 51.293 | 68.491 | 93.148 |
| Total des frais de vente/Généraux/Admin | 25.899 | 30.637 | 32.328 | 47.958 |
| Recherche et développement | 8.188 | 10.468 | 10.818 | 12.789 |
| Charges (revenus) inhabituelles | 5.602 | 4.114 | 0.818 | -0.676 |
| Produits d'exploitation | -23.663 | -26.741 | -22.934 | -38.642 |
| Produits (charges) d'intérêts, nets Hors exploitation | -2.892 | -2.953 | -7.586 | -4.508 |
| Autres, nets | 0.389 | -1.032 | -0.83 | -0.009 |
| Résultat net avant impôts | -26.166 | -30.726 | -31.35 | -43.159 |
| Résultat net après impôts | -26.166 | -30.726 | -31.35 | -43.159 |
| Résultat net avant éléments extra | -26.166 | -30.726 | -31.35 | -43.159 |
| Résultat net | -26.166 | -30.726 | -31.35 | -43.159 |
| Revenu disponible pour les actionnaires ordinaires, hors éléments exceptionnels | -26.166 | -30.726 | -31.35 | -43.159 |
| Bénéfice disponible pour les actionnaires ordinaires, y compris les éléments exceptionnels | -26.166 | -30.726 | -31.35 | -43.159 |
| Résultat net dilué | -26.166 | -30.726 | -31.35 | -43.159 |
| Moyenne pondérée des actions diluées | 26.2541 | 26.2541 | 26.5615 | 27.365 |
| BPA dilué hors éléments extraordinaires | -0.99665 | -1.17033 | -1.18028 | -1.57716 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | ||
| BPA dilué normalisé | -0.78327 | -1.01363 | -1.14948 | -1.60186 |
| Depreciation / Amortization | 2.529 | 2.559 |
| Q1 2021 | Q2 2021 | Q3 2021 | Q4 2021 | Q1 2022 | |
|---|---|---|---|---|---|
| Revenu total | 28.866 | 11.885 | 6.531 | 7.224 | 6.548 |
| Revenu | 28.866 | 11.885 | 6.531 | 7.224 | 6.548 |
| Coût des recettes, total | 18.218 | 7.085 | 2.722 | 2.493 | 3.235 |
| Résultat brut | 10.648 | 4.8 | 3.809 | 4.731 | 3.313 |
| Total des frais d'exploitation | 35.177 | 22.472 | 16.499 | 19 | 21.009 |
| Total des frais de vente/Généraux/Admin | 11.927 | 11.425 | 13.607 | 13.558 | 14.487 |
| Recherche et développement | 3.321 | 3.323 | 3.293 | 2.852 | 3.206 |
| Charges (revenus) inhabituelles | 1.711 | 0.639 | -3.123 | 0.097 | 0.081 |
| Produits d'exploitation | -6.311 | -10.587 | -9.968 | -11.776 | -14.461 |
| Produits (charges) d'intérêts, nets Hors exploitation | -0.651 | -0.815 | -1.546 | -1.496 | -1.137 |
| Autres, nets | 0.001 | 0 | 0 | -0.01 | 0.012 |
| Résultat net avant impôts | -6.961 | -11.402 | -11.514 | -13.282 | -15.586 |
| Résultat net après impôts | -6.961 | -11.402 | -11.514 | -13.282 | -15.586 |
| Résultat net avant éléments extra | -6.961 | -11.402 | -11.514 | -13.282 | -15.586 |
| Résultat net | -6.961 | -11.402 | -11.514 | -13.282 | -15.586 |
| Revenu disponible pour les actionnaires ordinaires, hors éléments exceptionnels | -6.961 | -11.402 | -11.514 | -13.282 | -15.586 |
| Bénéfice disponible pour les actionnaires ordinaires, y compris les éléments exceptionnels | -6.961 | -11.402 | -11.514 | -13.282 | -15.586 |
| Résultat net dilué | -6.961 | -11.402 | -11.514 | -13.282 | -15.586 |
| Moyenne pondérée des actions diluées | 26.604 | 27.73 | 28.051 | 27.059 | 31.07 |
| BPA dilué hors éléments extraordinaires | -0.26165 | -0.41118 | -0.41047 | -0.49085 | -0.50164 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| BPA dilué normalisé | -0.19734 | -0.38814 | -0.5218 | -0.48727 | -0.49903 |
- Annuel
- Trimestriel
| 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|
| Total de l'actif à court terme | 9.913 | 12.7 | 86.14 | 43.613 |
| Espèces et placements à court terme | 5.914 | 5.286 | 62.126 | 32.712 |
| Trésorerie et équivalents | 5.914 | 5.286 | 62.126 | 32.712 |
| Total des créances, nettes | 1.892 | 5.292 | 15.304 | 3.656 |
| Accounts Receivable - Trade, Net | 1.892 | 5.292 | 15.304 | 3.656 |
| Other Current Assets, Total | 2.107 | 2.122 | 8.71 | 7.245 |
| Total Assets | 39.057 | 41.633 | 121.07 | 76.097 |
| Property/Plant/Equipment, Total - Net | 1.388 | 2.12 | 3.178 | 4.179 |
| Property/Plant/Equipment, Total - Gross | 6.956 | 8.506 | 9.902 | 10.928 |
| Accumulated Depreciation, Total | -5.568 | -6.386 | -6.724 | -6.749 |
| Goodwill, Net | 10.804 | 11.631 | 15.031 | 15.031 |
| Intangibles, Net | 16.852 | 15.092 | 13.26 | 11.617 |
| Other Long Term Assets, Total | 0.1 | 0.09 | 3.461 | 1.657 |
| Total Current Liabilities | 4.468 | 22.6 | 32.125 | 28.96 |
| Accounts Payable | 0.886 | 1.717 | 8.964 | 1.662 |
| Accrued Expenses | 1.568 | 1.899 | 4.69 | 4.899 |
| Notes Payable/Short Term Debt | 0 | 12.045 | 0 | 0 |
| Other Current Liabilities, Total | 2.014 | 6.939 | 6.631 | 22.38 |
| Total Liabilities | 53.125 | 76.213 | 79.904 | 56.37 |
| Total Long Term Debt | 23.099 | 23.812 | 15.926 | 9.993 |
| Long Term Debt | 23.099 | 23.812 | 15.926 | 9.993 |
| Other Liabilities, Total | 25.558 | 29.801 | 31.853 | 17.417 |
| Total Equity | -14.068 | -34.58 | 41.166 | 19.727 |
| Redeemable Preferred Stock | 183.962 | 193.959 | 0 | 0 |
| Common Stock | 0.001 | 0.001 | 0.027 | 0.031 |
| Additional Paid-In Capital | 2.107 | 2.324 | 299.953 | 321.669 |
| Retained Earnings (Accumulated Deficit) | -200.138 | -230.864 | -258.814 | -301.973 |
| Total Liabilities & Shareholders’ Equity | 39.057 | 41.633 | 121.07 | 76.097 |
| Total Common Shares Outstanding | 26.2541 | 26.2541 | 26.5615 | 30.7896 |
| Current Port. of LT Debt/Capital Leases | 0 | 11.84 | 0.019 |
| Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
|---|---|---|---|---|---|
| Total de l'actif à court terme | 81.244 | 68.45 | 56.445 | 43.613 | 27.233 |
| Espèces et placements à court terme | 55.329 | 56.349 | 47.913 | 32.712 | 16.427 |
| Trésorerie et équivalents | 55.329 | 56.349 | 47.913 | 32.712 | 16.427 |
| Total des créances, nettes | 18.367 | 5.281 | 2.784 | 3.656 | 3.774 |
| Accounts Receivable - Trade, Net | 18.367 | 5.281 | 2.784 | 3.656 | 3.774 |
| Other Current Assets, Total | 7.548 | 6.82 | 5.748 | 7.245 | 7.032 |
| Total Assets | 115.486 | 101.804 | 89.997 | 76.097 | 61.651 |
| Property/Plant/Equipment, Total - Net | 3.387 | 3.378 | 4.432 | 4.179 | 6.247 |
| Property/Plant/Equipment, Total - Gross | 10.369 | 10.471 | 11.827 | 10.928 | 13.409 |
| Accumulated Depreciation, Total | -6.982 | -7.093 | -7.395 | -6.749 | -7.162 |
| Goodwill, Net | 15.031 | 15.031 | 15.031 | 15.031 | 15.031 |
| Intangibles, Net | 12.821 | 12.4 | 11.992 | 11.617 | 11.131 |
| Other Long Term Assets, Total | 3.003 | 2.545 | 2.097 | 1.657 | 2.009 |
| Total Current Liabilities | 16.124 | 21.272 | 22.787 | 28.96 | 29.811 |
| Accounts Payable | 3.747 | 1.16 | 1.6 | 1.662 | 2.12 |
| Accrued Expenses | 2.622 | 2.959 | 3.533 | 4.899 | 4.597 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 2.707 | 3.106 | 0.02 | 0.019 | 0.051 |
| Other Current Liabilities, Total | 7.048 | 14.047 | 17.634 | 22.38 | 23.043 |
| Total Liabilities | 79.054 | 76.031 | 73.964 | 56.37 | 53.87 |
| Total Long Term Debt | 30.328 | 29.955 | 29.975 | 9.993 | 10.055 |
| Long Term Debt | 30.328 | 29.955 | 29.975 | 9.993 | 10.055 |
| Other Liabilities, Total | 32.602 | 24.804 | 21.202 | 17.417 | 14.004 |
| Total Equity | 36.432 | 25.773 | 16.033 | 19.727 | 7.781 |
| Redeemable Preferred Stock | 0 | 0 | 0 | 0 | |
| Common Stock | 0.027 | 0.027 | 0.027 | 0.031 | 0.032 |
| Additional Paid-In Capital | 302.18 | 302.923 | 304.697 | 321.669 | 325.308 |
| Retained Earnings (Accumulated Deficit) | -265.775 | -277.177 | -288.691 | -301.973 | -317.559 |
| Total Liabilities & Shareholders’ Equity | 115.486 | 101.804 | 89.997 | 76.097 | 61.651 |
| Total Common Shares Outstanding | 26.7854 | 26.9489 | 27.0201 | 30.7896 | 31.8893 |
- Annuel
- Trimestriel
| 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|
| Revenu net/Ligne de départ | -26.166 | -30.726 | -31.35 | -43.159 |
| Liquidités provenant des activités d'exploitation | -17.677 | -21.726 | -21.366 | -28.223 |
| Liquidités provenant des activités d'exploitation | 1.74 | 2.793 | 2.903 | 3.178 |
| Éléments non monétaires | 6.496 | 7.852 | 11.882 | 7.167 |
| Variation du fonds de roulement | 0.253 | -1.645 | -4.801 | 4.591 |
| Flux de trésorerie liés aux activités d'investissement | -0.617 | -1.872 | -2.927 | -2.547 |
| Dépenses d'investissement | -0.617 | -1.416 | -2.177 | -2.547 |
| Autres éléments de flux de trésorerie d'investissement, total | 0 | -0.456 | -0.75 | 0 |
| Flux de trésorerie provenant des activités de financement | 19.032 | 22.972 | 81.131 | 1.262 |
| Éléments de flux de trésorerie de financement | -0.283 | -0.119 | -8.249 | -0.5 |
| Émission (remboursement) d'actions, nette | 8.55 | 10.047 | 73.34 | 17.112 |
| Émission (remboursement) de la dette, nette | 10.765 | 13.044 | 16.04 | -15.35 |
| Variation nette de la trésorerie | 0.738 | -0.626 | 56.838 | -29.508 |
| Intérêts payés en espèces | 1.844 | 1.676 |
| Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -6.961 | -18.363 | -29.877 | -43.159 | -15.586 |
| Cash From Operating Activities | -11.326 | -10.236 | -18.026 | -28.223 | -13.099 |
| Cash From Operating Activities | 0.746 | 1.523 | 2.323 | 3.178 | 0.908 |
| Non-Cash Items | 3.721 | 5.336 | 4.704 | 7.167 | 2.674 |
| Changes in Working Capital | -8.832 | 1.268 | 4.824 | 4.591 | -1.095 |
| Cash From Investing Activities | -0.516 | -0.864 | -1.906 | -2.547 | -0.352 |
| Capital Expenditures | -0.516 | -0.864 | -1.906 | -2.547 | -0.352 |
| Other Investing Cash Flow Items, Total | 0 | 0 | 0 | 0 | |
| Cash From Financing Activities | 4.951 | 5.229 | 5.625 | 1.262 | -2.834 |
| Financing Cash Flow Items | -0.108 | -0.109 | 0.232 | -0.5 | -4.6 |
| Issuance (Retirement) of Stock, Net | 0.475 | 0.679 | 0.739 | 17.112 | 1.674 |
| Issuance (Retirement) of Debt, Net | 4.584 | 4.659 | 4.654 | -15.35 | 0.092 |
| Net Change in Cash | -6.891 | -5.871 | -14.307 | -29.508 | -16.285 |
| Cash Interest Paid | 0.223 |
| Nom de l'investisseur | Catégorie de l'investisseur | Pourcentage de l'encours | Actions détenues | Changement d'actions | Date d'avoirs | Taux du chiffre d'affaires |
|---|---|---|---|---|---|---|
| Schuler (Jack W) | Individual Investor | 27.8328 | 19952112 | 8695652 | 2022-11-21 | LOW |
| Kennedy (Lawrence T Jr.) | Individual Investor | 20.684 | 14827404 | 0 | 2023-01-03 | MED |
| Patience (John) | Individual Investor | 9.7923 | 7019695 | 1739130 | 2022-11-21 | LOW |
| Birchview Capital, LP | Investment Advisor | 7.0302 | 5039633 | 2884624 | 2022-12-31 | LOW |
| Cawthorn (Robert E) | Individual Investor | 5.0948 | 3652220 | 1723341 | 2022-11-21 | LOW |
| Strobeck (Matthew W) | Individual Investor | 4.052 | 2904668 | 1304345 | 2022-11-21 | LOW |
| Industrial Development Funding LLC | Corporation | 2.6454 | 1896374 | 0 | 2022-03-01 | LOW |
| Wells Fargo Advisors | Research Firm | 1.0724 | 768725 | 221413 | 2022-09-30 | LOW |
| Essex Investment Management Company, LLC | Investment Advisor/Hedge Fund | 0.5273 | 377994 | -29 | 2022-12-31 | LOW |
| Life Sciences Alternative Financing, L.L.C. | Corporation | 0.4102 | 294053 | 0 | 2022-03-01 | LOW |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 0.3343 | 239656 | 59660 | 2022-09-30 | LOW |
| Cannell & Co. | Investment Advisor | 0.2868 | 205605 | 0 | 2022-12-31 | LOW |
| Hutton Scott | Individual Investor | 0.2389 | 171227 | 96218 | 2022-11-21 | LOW |
| Massarany (Hany) | Individual Investor | 0.1924 | 137934 | 130434 | 2022-11-21 | HIGH |
| Endurant Capital Management LP | Hedge Fund | 0.1815 | 130136 | -617 | 2022-09-30 | HIGH |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.1731 | 124070 | 27282 | 2022-09-30 | LOW |
| Millennium Management LLC | Hedge Fund | 0.1647 | 118048 | 728 | 2022-09-30 | HIGH |
| Bridgeway Capital Management, LLC | Investment Advisor | 0.1395 | 100000 | 50000 | 2022-09-30 | LOW |
| Pestano (Gary Anthony) | Individual Investor | 0.1294 | 92732 | 3474 | 2022-11-10 | |
| Cowie (Robin Harper) | Individual Investor | 0.1282 | 91920 | 25383 | 2022-11-21 | LOW |
Pourquoi choisir capital.com? Nos chiffres parlent d'eux-mêmes.
Capital.com Group +500000+
Tradeurs
93000+
Clients actifs par mois
$57000000+
Volume d'investissement par mois
$31000000+
Essayez maintenant Retrait par mois
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
Trade commission
0
- 1:1
- 2:1
- 5:1
- 10:1
- 20:1
Effet de levier
20:1
- 20
- 100
- 500
- 1000
- 10000
Investment
Trade size (Leverage x Investement):
Ouverture
Clôture
Short Long
Biodesix, Inc. Company profile
À propos de Biodesix, Inc.
Biodesix, Inc. est une société basée aux États-Unis qui développe et commercialise des tests de diagnostic sanguins pour l'oncologie. Le produit de la société, Biodesix Lung Reflex, intègre des résultats sanguins génomiques et protéomiques pour révéler les deux aspects du cancer du poumon. Son test GeneStrat offre des résultats sanguins sur les mutations dans les 72 heures pour les patients atteints de cancer du poumon non à petites cellules (NSCLC). Son test VeriStrat fournit des informations protéomiques prédictives et pronostiques basées sur le sang avec les patients atteints de cancer du poumon non à petites cellules (NSCLC) dont le test est négatif pour les mutations de l'EGFR (EGFR de type sauvage) ou dont le statut de mutation de l'EGFR est inconnu.
| Industry: | Medical & Diagnostic Laboratories |
Suite 100
2970 Wilderness Place
BOULDER
COLORADO 80301
US
Compte de résultat
- Annual
- Quarterly
Les gens regardent aussi
Êtes-vous toujours à la recherche d'un broker de confiance?
Rejoignez les plus de 500 000 traders du monde entier qui ont choisi de trader avec Capital.com